Literature DB >> 22955861

Surgical correction of gynecomastia with minimal scarring.

Jun-Ho Lee1, Il-Kug Kim, Tae-Gon Kim, Yong-Ha Kim.   

Abstract

BACKGROUND: Gynecomastia is a benign, excessive development of the male breast that occurs at an overall incidence of 32-36 %. The authors effectively removed peripheral fat tissues with power-assisted liposuction (PAL) and periareolar glandular tissues with a cartilage shaver in a series of patients. The small periareolar incisions were not easily recognized.
METHODS: Between February 2010 and April 2012, the charts of 15 patients (28 breasts) treated with PAL and a cartilage shaver were retrospectively reviewed.
RESULTS: The mean volume of fat tissue removed with liposuction was 319 mL, and the mean volume of glandular tissue removed with the cartilage shaver was 70 mL. The mean follow-up period was 11.2 months. No infection, nipple-areola complex necrosis, nipple retraction, or saucer deformity was encountered in this series. Intraoperative bleeding occurred in one patient. Mild asymmetries developed in three patients.
CONCLUSIONS: Use of PAL and a cartilage shaver for the treatment of gynecomastia allows for effective removal of both the fat and the glandular tissue of the breast through a minimal periareolar incision. This technique can achieve excellent aesthetic results with inconspicuous scarring. LEVEL OF EVIDENCE IV: This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266 .

Entities:  

Mesh:

Year:  2012        PMID: 22955861     DOI: 10.1007/s00266-012-9970-6

Source DB:  PubMed          Journal:  Aesthetic Plast Surg        ISSN: 0364-216X            Impact factor:   2.326


  1 in total

1.  Periareolar incision for the management of benign breast tumors.

Authors:  Xiangnan Kong; Xi Chen; Liyu Jiang; Tingting Ma; Baosan Han; Qifeng Yang
Journal:  Oncol Lett       Date:  2016-09-12       Impact factor: 2.967

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.